26 May 2023
A study published in Cell Metabolism has suggested that the commonly used medicine for type 2 diabetes, canagliflozin, may be repurposed to treat T-cell driven autoimmunity as the medicine reduces T-cell activation. The scientists hope to move the study to clinical trials.
CEO vacancy, The Pituitary Foundation (Bristol)
29 Apr 2024
Volunteer and Support Services Coordinator, The Pituitary Foundation (London)
29 Apr 2024
Graduate Teaching Assistant Vacancy, University of Reading
29 Apr 2024
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024